WEBULL

Novo Nordisk (CPSE:NOVO B): Revisiting Valuation After a 21% Three-Month Share Price Pullback

Simply Wall St · 2d ago

Short term slide and longer term context

Novo Nordisk (CPSE:NOVO B) has quietly slipped over the past few months, with the stock down about 1 % this month and roughly 21 % over the past 3 months, inviting closer attention.

See our latest analysis for Novo Nordisk.

Zooming out, the recent pullback sits against a much tougher backdrop, with a steep year to date share price return decline and a similarly weak 1 year total shareholder return suggesting momentum has clearly cooled despite solid underlying earnings growth.

If Novo Nordisk’s reset has you rethinking healthcare exposure, this could be a good moment to explore other healthcare stocks that pair defensive cash flows with long term growth stories.

With shares now well below recent highs, while analysts still see upside and earnings are holding up, investors face a key question: is Novo Nordisk undervalued today, or is the market already pricing in its next leg of growth?

Most Popular Narrative: 21.6% Undervalued

Against a last close of DKK 308.15, the most followed narrative puts Novo Nordisk’s fair value materially higher, framing today’s weakness as a potential discount.

The analysts have a consensus price target of DKK465.3 for Novo Nordisk based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of DKK620.0, and the most bearish reporting a price target of just DKK340.0.

Read the complete narrative.

Want to see what justifies paying far above today’s price? The narrative leans on steady growth, firm margins, and a richer future earnings multiple. Curious which projections actually drive that gap?

Result: Fair Value of $393.29 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, several risks loom, including intensifying GLP 1 competition and potential pricing or reimbursement pushback that could quickly erode the upside case.

Find out about the key risks to this Novo Nordisk narrative.

Build Your Own Novo Nordisk Narrative

If you want to stress test these assumptions or lean on your own due diligence instead, you can build a complete view in minutes: Do it your way.

A great starting point for your Novo Nordisk research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.

Looking for more investment ideas?

Before you move on, sharpen your watchlist with fresh opportunities tailored to different strategies, so you do not miss the next wave of market leaders.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.